FridayOL

Novo Nordisk: Can It Sustain Momentum Beyond Wegovy's Patent?

Financial Times

Novo Nordisk has become a Wall Street darling, largely fueled by the phenomenal success of its weight-loss drug, Wegovy. But the question on many investors' minds is: can the company maintain this impressive growth trajectory once its patent expires ...Read more